KRAS and neoplasm: TP53 and KRAS are prevalent oncogenic drivers in most tumor types, and their cooccurring mutations result in the upregulation of tumor immunogenicity and immune tolerance/escape in response to PD-1 blockade immunotherapy in LUAD (51).